Clinical Trial Update: A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of MK-6096 for migraine prophylaxis has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Headache
• Migraine

Drugs mentioned

• MK-6096

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Migraine, Headache | Phase 2 | Status: COMPLETED | Results posted: 2016-07-20